Wave Life Sciences is a biotechnology business based in the US. Wave Life Sciences shares (WVE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.26 – a decrease of 4.93% over the previous week. Wave Life Sciences employs 266 staff and has a trailing 12-month revenue of around $53.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $14.26 |
|---|---|
| 52-week range | $3.50 - $16.74 |
| 50-day moving average | $10.40 |
| 200-day moving average | $6.77 |
| Wall St. target price | $22.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.12 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.21 from 2024-11-19
| 1 week (2024-11-14) | -5.27% |
|---|---|
| 1 month (2024-10-21) | -5.96% |
| 3 months (2024-08-21) | 142.91% |
| 6 months (2024-05-21) | 124.84% |
| 1 year (2023-11-21) | 170.67% |
|---|---|
| 2 years (2022-11-21) | 256.14% |
| 3 years (2021-11-19) | 229.70% |
| 5 years (2019-11-21) | 30.33 |
| Revenue TTM | $53.6 million |
|---|---|
| Operating margin TTM | 832.66% |
| Gross profit TTM | $-73,644,000 |
| Return on assets TTM | -34.04% |
| Return on equity TTM | -243.82% |
| Profit margin | -265.84% |
| Book value | $0.95 |
| Market Capitalization | $2.3 billion |
TTM: trailing 12 months
We're not expecting Wave Life Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Wave Life Sciences's shares have ranged in value from as little as $3.5 up to $16.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Wave Life Sciences's is -1.208. This would suggest that Wave Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Wave Life Sciences has bucked the trend.
Wave Life Sciences Ltd. , a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.